Li Feng, Na Zhao, Xun Yao, Xin Sun, Liang Du, Xiang Diao, Shengfu Li, Youping Li – 30 July 2007 – University of Wisconsin (UW) solution has been recognized as the gold standard in liver preservation, but its limitations are becoming obvious, such as risk of biliary complications and its high cost. Alternatively, the effects of histidine‐tryptophan‐ketoglutarate (HTK), such as improved biliary protection and low cost, have been observed. This systematic review is conducted to compare the efficacy and safety of these 2 solutions. Databases from 1966 to June 2006 were searched.

Yong‐Jae Kim, Gi‐Young Ko, Hyun‐Ki Yoon, Ji‐Hoon Shin, Heung‐Kyu Ko, Kyu‐Bo Sung – 30 July 2007 – The purpose of this research was to evaluate the intermediate effectiveness of intraoperative portal vein stent placement for portal venous stenosis in liver transplantation. We attempted intraoperative portal vein stent placement in 44 portal venous anastomotic stenoses in 36 patients. All patients underwent stent placement via either the inferior or superior mesenteric vein.

Satoshi Yokoyama, Mureo Kasahara, Akinari Fukuda, Shinji Uemoto, Shunsuke Nosaka – 30 July 2007

Tomasz Laskus, Jeffrey Wilkinson, Roksana Karim, Wendy Mack, Marek Radkowski, Marina deGiacomo, Jonathan Nasseri, Zhi Chen, Jiaao Xu, Andrea Kovacs – 27 July 2007 – Despite the high frequency of HCV and HIV coinfection, little is known about HCV quasispecies in HIV‐positive patients. The current analysis included 236 HIV+/anti‐HCV+ women enrolled in the Women's Interagency HIV Study (WIHS). Hypervariable region 1 of the second envelope gene was analyzed by single‐strand conformation polymorphism (SSCP).

Richard B. Freeman – 27 July 2007

Laurent Bellest, Valérie Eschwège, Raoul Poupon, Olivier Chazouillères, Annie Robert – 27 July 2007 – International Normalized Ratio (INR), which standardizes prothrombin time (PT) during oral anticoagulation, has been extended to standardize PT in liver diseases and is included in prognostic models such as the Model for End stage Liver Disease (MELD). However, mechanisms of PT prolongation in liver diseases differ from those involved in oral anticoagulation, and the thromboplastin reagents differ in their sensitivities to these 2 mechanisms.

Javid Fazili, Teddy F. Bader, William Tierney – 27 July 2007

Tommaso Stroffolini, Giovanni Battista Gaeta, Alfonso Mele – 27 July 2007

Maria Serena Longhi, Munther J. Hussain, Dimitrios P. Bogdanos, Alberto Quaglia, Giorgina Mieli‐Vergani, Yun Ma, Diego Vergani – 27 July 2007 – Autoimmune hepatitis type 2 (AIH‐2) is a severe organ‐specific disorder characterized by liver kidney microsomal antibody type 1 targeting cytochrome P4502D6 (CYP2D6). Growing evidence implicates the involvement of CD8 T cell immune responses in its pathogenesis. We investigated CYP2D6‐specific CD8 T cell human leukocyte antigen (HLA)‐A2 restricted responses in AIH‐2 (20 patients, 11 HLA‐A2+).

Armando Tripodi, Veena Chantarangkul, Massimo Primignani, Federica Fabris, Alessandra Dell'Era, Cinzia Sei, Pier Mannuccio Mannucci – 27 July 2007 – The model for end‐stage‐liver‐disease (MELD) is a mathematical score used to prioritize patients for liver transplantation and includes results for creatinine, bilirubin, and prothrombin time (PT) expressed as international normalized ratio (INR).